Drug
D1104 | surinabant
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 33.08±16.61 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 19.95 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 34.31±22.53 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| 1H-Pyrazole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-1-piperidinyl- | 288104-79-0 | 5-(4-Bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide; |
| 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide | 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide | BDBM50171290 |
| BRD-K09557221-001-01-6 | CAS-288104-79-0 | CHEBI:125484 |
| CHEMBL189676 | DA-38649 | DB13070 |
| DSSTox_CID_27357 | DSSTox_GSID_47357 | DSSTox_RID_82293 |
| DTXSID2047357 | FT-0766481 | GTPL9233 |
| LS-193786 | NCGC00247959-01 | NCGC00254070-01 |
| Q7646304 | SCHEMBL675894 | SF8R9VCB0X |
| SR 147778 | SR-147778 | SR147778 |
| Surinabant | Surinabant [INN] | Tox21_300239 |
| UNII-SF8R9VCB0X | ZINC000001549068 | ZINC1549068 |